¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"lupus erythematosus factor"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • behavioral risk factor
    ÇൿÀ§Çè¿äÀÎ
  • coagulation factor
    ÀÀ°íÀÎÀÚ
  • coagulation factor inhibitor
    ÀÀ°íÀÎÀÚ¾ïÁ¦Á¦
  • colony-stimulating factor
    Áý¶ôÀÚ±ØÀÎÀÚ
  • common factor
    °øÅëÀÎÀÚ
  • competence factor
    1. ¸é¿ª°¡´ÉÀÎÀÚ 2. ¹ÝÀÀ°¡´ÉÀÎÀÚ
  • competence inducing factor
    ¸é¿ª°¡´ÉÀ¯¹ßÀÎÀÚ
  • complementary factor
    º¸ÃæÀÎÀÚ
  • conglutinogen activating factor
    ±³Âø¿øÈ°¼ºÀÎÀÚ
  • conversion factor
    º¯È¯ÀÎÀÚ, º¯È¯°è¼ö
  • carcinogenic factor
    ¹ß¾ÏÀÎÀÚ
  • corticotropin-releasing factor
    ºÎ½Å°ÑÁúÀÚ±ØÈ£¸£¸ó¹æÃâÀÎÀÚ
  • chemotactic factor
    È­Çнò¸²ÀÎÀÚ
  • drug resistance factor
    ¾àÁ¦ÀúÇ×ÀÎÀÚ
  • dermonecrotic factor
    ÇǺα«»çÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • carcinogenic factor
    ¹ß¾ÏÀÎÀÚ
  • chemotactic factor
    È­ÇÐÁÖ¼ºÀÎÀÚ, È­Çнò¸²ÀÎÀÚ
  • coagulation factor
    ÀÀ°íÀÎÀÚ
  • coagulation factor inhibitor
    ÀÀ°íÀÎÀÚ¾ïÁ¦Á¦
  • colony-stimulating factor
    Áý¶ôÀÚ±ØÀÎÀÚ
  • common factor
    °øÅëÀÎÀÚ
  • competence factor
    Àû°ÝÀÎÀÚ
  • competence inducing factor
    Àû°ÝÀ¯¹ßÀÎÀÚ
  • complementary factor
    º¸ÃæÀÎÀÚ, º¸Ã¼ÀÎÀÚ
  • conglutinogen activating factor
    ±³Âø¿øÈ°¼ºÀÎÀÚ
  • conversion factor
    º¯È¯ÀÎÀÚ, º¯È¯°è¼ö
  • corticotropin releasing factor
    ºÎ½Å°ÑÁúÀÚ±ØÈ£¸£¸ó¹æÃâÀÎÀÚ
  • decay accelerating factor
    ºØ±«ÃËÁøÀÎÀÚ
  • dermonecrotic factor
    ÇǺα«»çÀÎÀÚ
  • diabetogenic factor
    ´ç´¢À¯¹ßÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • Fibroblast growth factor
    ¼¶À¯¸ð¼¼Æ÷(àéë«Ù½á¬øà)¼ºÀå¿äÀÎ(à÷íþé©ì×)
  • G-CSF (Granulocyte colony-stimulating factor)
    °ú¸³¼¼Æ÷±ºÃËÁøÀÎÀÚ(Î¨Ø£á¬øàÏØõµòäì×í­)
  • GH releasing factor
    ¼ºÀå(à÷íþ)È£¸£¸ó À¯¸®ÀÎÀÚ(ë´×îì×í­).
  • GH releasing factor
    ¼ºÀåÈ£¸£¸óÀ¯¸®ÀÎÀÚ.
  • Growth factor
    ¼ºÀåÀÎÀÚ(à÷íþì×í­)
  • Hageman factor
    ÇϰԸ¸ÀÎÀÚ
  • Hydrostatic factor
    Á¤¼öÀÎÀÚ(ð¡â©ì×í­)
  • IGF-I(insulin-like growth factor-I)
    Àν¶¸° À¯»ç ¼ºÀåÀÎÀÚ-1
  • Luteinization -inhibiting factor
    Ȳüȭ¾ïÁ¦¿äÀÎ(üÜô÷ûùåäð¤é©ì×)
  • Macrophage colony-stimulating factor
    ´ë½Ä¼¼Æ÷Áý¶ôÇü¼ºÃËÁøÀÎÀÚ(ÓÞãÝá¬øàó¢Õªû¡à÷õµòäì×í­)à÷õµòäì×?
  • NGF=>nerve growth factor
    ½Å°æ¼ºÀåÀÎÀÚ
  • PAF =platelet activating factor
    Ç÷¼ÒÆÇȰ¼ºÀÎÀÚ.
  • PAF= platelet activating factor
    Ç÷¼ÒÆÇ Ȱ¼ºÀÎÀÚ.
  • Q factor
    Å¥ ÀÎÀÚ
  • Q-factor
    Å¥-ÀÎÀÚ (ì×í­)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • systemic lupus erythematosus
    Àü½Å¼º È«¹Ý¼º(îïãóàõûõÚèàõ)·çǪ½º.
  • systemic lupus erythematosus
    Àü½Å¼º È«¹Ý¼º(îïãóàõûõÚèàõ)·çǪ½º
  • col factor(»ýÈ­) cÀÌ ÀÎÀÚ colicin factor
    Äݸ®½ÅÀÎÀÚ.
  • time, dose and fractionation factor, TDF factor
    ½Ã°£¼±·®ºÐÇÒÀÎÀÚ
  • lichen planus erythematosus<³ª>
    È«¹Ý¼º ÆíÆòż±
  • pemphigus erythematosus
    È«¹Ý¼º õÆ÷â(ûõÚèàõ ô¸øÞóê)
  • pemphigus erythematosus ³ª
    È«¹Ý¼º(ûõÚèàõ) õÆ÷â
  • pemphigus erythematosus ³ª
    È«¹Ý¼º õÆ÷â(ûõÚèàõ ô¸øÞóê)
  • chilblain lupus
    µ¿Ã¢·çǪ½º
  • cutaneous subacute lupus
    ÇǺΠ¾Æ±Þ¼º ·çǪ½º
  • discoid lupus
    ¿øÆÇ»ó·çǪ½º
  • drug-induced lupus
    ¾à¹°À¯¹ß·çǪ½º
  • lupus
    ·çǪ½º
  • lupus anticoagulant
    ·çǪ½ºÇ×ÀÀ°í¹°Áú
  • lupus anticoagulant
    ·çǪ½ºÇ×ÀÀ°íÀÎÀÚ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • calcium-activated factor
    Ä®½·ºÎȰ ÀÎÀÚ(Ý·üÀì×í­)
  • cell factor
    ¼¼Æ÷ÀÎÀÚ(á¬øàì×í­)
  • chloroplast coupling factor
    ¿±·Ïü(ç¨Öàô÷) ¦ÁöÀ½ÀÎÀÚ(ì×í­)
  • Christmas factor
    Å©¸®½º¸¶½º ÀÎÀÚ(ì×í­)
  • citrovorum factor
    "½ÃÆ®·Îº¸·ë ÀÎÀÚ,"
  • clearance factor
    ûÁ¤ÀÎÀÚ(ôèïäì×í­)
  • clot-promoting factor
    ÀÀ±«ÃËÁøÀÎÀÚ(ëêÎÕõµòäì×í­)
  • Col factor
    Col ÀÎÀÚ(ì×í­)
  • colicin factor
    Äݸ®½Å ÀÎÀÚ(ì×í­)
  • colicinogenic factor
    Äݸ®½Å »ý¼ºÀÎÀÚ(ßæà÷ì×í­)
  • colony-stimulating factor
    ÄݷδÏÀÚ±Ø ÀÎÀÚ(í©Ð½ì×í­)
  • contact factor
    "Á¢ÃËÀÎÀÚ(ïÈõºì×í­), (ÔÒ) Hageman factor"
  • conversion factor
    ÀüȯÀÎÀÚ(ï®üµì×í­)
  • cord factor
    ÄÚµå ÀÎÀÚ(ì×í­)
  • coupling factor
    ¦Áþ±â ÀÎÀÚ(ì×í­)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
LE lactate extraction; left ear; left eye; leukocyte elastase; leukoerythrogenic; live embryo; Long Eva...
LED light-emitting diode; lowest emitting dose; lupus erythematosus disseminatus
LES Lambert-Eaton syndrome; Lawrence Experimental Station [agar]; local excitatory state; Locke egg seru...
NLE neonatal lupus erythematosus
SCLE subacute cutaneous lupus erythematosus
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
LN Lupus Nephritis
LBT Lupus band test
SLAM Systemic Lupus Activity Measure
SLE Systemic Lupus Erytematosus
SLICC/ACR Systemic Lupus International Collaborating Clinics/American College of Rheumatology
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • atrial natriuretic factor
    ½É¹æ¼º ³ªÆ®·ý ÀÌ´¢ ÀÎÀÚ
  • attenuation factor
    °¨¾à ¿ä¼Ò, °¨¼è ¿äÀÎ
  • B cell growth factor
    B ¼¼Æ÷ ¼ºÀå ÀÎÀÚ, B ¼¼Æ÷ Áõ½Ä ÀÎÀÚ
    B ¼¼Æ÷°¡ ÇüÁú ¼¼Æ÷·Î ºÐÈ­ÇÏ´Â °úÁ¤Àº Å©°Ô 2´Ü°è·Î ³ª´©¾îÁø´Ù. Ç׿ø ÀÚ±ØÀ» ¹ÞÀº B ¼¼Æ÷´Â ¿ì¼± Áõ½ÄÇϰí, ±× ÈÄ¿¡ Ç×ü¸¦ »ý»êÇÏ¿© ºÐºñÇÏ´Â ÇüÁú ¼¼Æ÷·Î ºÐÈ­¸¦ ¿Ï¼öÇÑ´Ù. Ç׿ø ÀÚ±ØÀ» ¹ÞÀº B ¼¼Æ÷´Â ±× ÀÚÁ¦¸¸À¸·Î´Â Áõ½ÄÇÏÁö ¸øÇϰí T¼¼Æ÷ À¯·¡ÀÇ B ¼¼Æ÷ Áõ½Ä ÀÎÀÚ³ª Ž½Ä ¼¼Æ÷ À¯·¡ ÀÎÀÚ IL-1ÀÇ ÀÚ±ØÀÌ Ãß°¡µÇ¾î Áõ½ÄÀ» ½ÃÀÛÇÑ´Ù. B ¼¼Æ÷ Áõ½Ä ÀÎÀÚ´Â Á¤»óÀÇ T¼¼Æ÷¸¦
  • B cell stimulating factor 1
    B ¼¼Æ÷ ÃËÁø ÀÎÀÚ 1
    µ¿ÀǾî´Â Interleukin 4·Î ¾Ë·ÁÁø ´ç´Ü¹éÀ¸·Î¼­ T ¼¼Æ÷, ºñ¸¸¼¼Æ÷ µî¿¡¼­ »ý»êµÈ´Ù. À̰ÍÀº B ¼¼Æ÷¿¡ ´ëÇØ comitogenÀ¸·Î ÀÛ¿ëÇϴµ¥ ±× ¿µÇâÀº B ¼¼Æ÷ÀÇ ¼º¼÷µµ¿¡ µû¶ó ´Ù¸£´Ù.
  • back scatter factor
    ÈÄ¹æ »ê¶õ °è¼ö
  • beam direction factor
    ¼±¼Ó ¹æÇâ ÀÎÀÚ
    ÀüÀÚÆÄ ¹æ»ç¼± ¶Ç´Â ÀÔÀÚ°¡ °°Àº ¹æÇâÀ¸·Î ¹æÃâÇÏ ´Â ¼Ó ¶Ç´Â ¼±ÀÇ ¹æÇâÀÇ ÀÎÀÚ.
  • behavioral factor
    Çൿ ¿äÀÎ
  • biological factor
    »ý¹°ÇÐÀû ¿äÀÎ
  • biotic factor
    »ý¹° ÀÎÀÚ
  • blood factor
    Ç÷¾× ÀÎÀÚ
  • bone factor
    °ñ ÀÎÀÚ
    Ȱ¼ºÀ̳ª ÀÚÁï¿¡ ´ëÇÑ Ä¡Á¶°ñÀÇ »ó´ë ¹ÝÀÀ.
  • Castle factor
    ij½½ ÀÎÀÚ
    ½ÄǰÀ̳ª À§¾× ¼Ó¿¡ ÀÖ´Â Ç׺óÇ÷ ÀÎÀÚ. À̰ÍÀÌ °áÇÌµÇ¸é ¾Ç¼º ºóÇ÷ÀÌ µÈ´Ù. À§¾×¿¡ ÇÔÀ¯µÈ ij½½³» ÀÎÀÚ¿Í ½Äǰ¿¡ ÇÔÀ¯µÈ ij½½¿Ü ÀÎÀÚ°¡ ÀÖ´Ù. ³»ÀÎÀÚ°¡ °áÇÌµÇ¸é ½Äǰ ³»ÀÇ ¿ÜÀÎÀÚ°¡ Èí¼öµÇÁö ¾Ê°í ¾Ç¼º ºóÇ÷ÀÌ ÀϾ´Ù. À§ ¾Ï µîÀ¸·Î À§¸¦ ÀüºÎ Àß¶ó¹ö¸®¸é ºóÇ÷ÀÌ ÀϾ´Â °ÍÀº ³»ÀÎÀÚ°¡ ¾ø¾îÁö±â ¶§¹®ÀÌ´Ù. ³»ÀÎÀÚ´Â ºÐÀÚ·® ¾à 10¸¸ÀÎ ´Ü¹éÁú·Î À§º®ÀÇ ¹æ ¼¼Æ÷¿¡¼­ ºÐºñµÈ´Ù. ¿ÜÀÎÀڷμ­´Â ºñŸ¹Î D°¡ °ü°èÇÑ´Ù. 1927³â ¹Ì±¹ÀÇ W.B. ij½½ÀÌ Ã³À½À¸·Î ÀÌ·¯ÇÑ ±¸Á¶¸¦ Á¦Ã¢ÇÏ¿´´Ù.
  • Castles extrinsic factor
    ij½½ ¿ÜÀÎÀÚ
  • cavity-gas calibration factor
    °­-±âü ±³Á¤ °è¼ö
  • certainty factor
    È®½Ç ¿äÀÎ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
lupus mutilans Cutaneous tuberculosis with extensive destruction of tissue.
(05 Mar 2000)
lupus nephritis Glomerulonephritis associated with systemic lupus erythematosus. It is classified into four histologic types: mesangial, focal, diffuse, and membranous.
(12 Dec 1998)
lupus papillomatosus A tuberculous skin lesion having a warty surface with a chronic inflammatory base seen on the hands in adults and lower extremities in children, with marked hypersensitivity to tuberculous antigens.
See: postmortem wart.
Synonym: lupus papillomatosus, lupus verrucosus, tuberculous wart, verrucous scrofuloderma.
(05 Mar 2000)
lupus pernio Sarcoid lesions, clinically resembling frostbite and microscopically resembling lupus vulgaris, involving ears, cheeks, nose, hands, and fingers.
(05 Mar 2000)
lupus profundus A subcutaneous panniculitis with marked lymphocyte infiltration of fat lobules giving rise to deep-seated, firm, rubbery nodules that sometimes become ulcerated, usually of the face; may occur in systemic and localised lupus erythematosus.
Synonym: lupus profundus.
(05 Mar 2000)
lupus sebaceus Lupus erythematosus with lesions on the face in butterfly areas.
(05 Mar 2000)
lupus serpiginosus A cutaneous tuberculous lesion that spreads peripherally, healing centrally with scar formation.
(05 Mar 2000)
lupus superficialis Skin disease in which there are red scaly patches, especially over the nose and cheeks. May be a symptom of systemic lupus erythematosus.
(18 Nov 1997)
lupus tuberculosus Cutaneous tuberculosis with characteristic nodular lesions on the face, particularly about the nose and ears.
Synonym: lupus tuberculosus, tuberculosis cutis luposa.
(05 Mar 2000)
lupus verrucosus A tuberculous skin lesion having a warty surface with a chronic inflammatory base seen on the hands in adults and lower extremities in children, with marked hypersensitivity to tuberculous antigens.
See: postmortem wart.
Synonym: lupus papillomatosus, lupus verrucosus, tuberculous wart, verrucous scrofuloderma.
(05 Mar 2000)
lupus vulgaris Cutaneous tuberculosis with characteristic nodular lesions on the face, particularly about the nose and ears.
Synonym: lupus tuberculosus, tuberculosis cutis luposa.
(05 Mar 2000)
accelerator factor <chemical> Heat- and storage-labile plasma glycoprotein which accelerates the conversion of prothrombin to thrombin in blood coagulation. Factor v accomplishes this by forming a complex with factor xa, phospholipid, and calcium (prothrombinase complex). Deficiency of factor v leads to owren's disease.
Chemical name: Blood-coagulation factor V
(12 Dec 1998)
acetate replacement factor <biochemistry> 1,2 dithiolane 3 valeric acid. Regarded as a coenzyme in the oxoglutarate dehydrogenase complex of the citric acid cycle. Involved generally in oxidative decarboxylations of _ keto acids. A growth factor for some organisms.
(18 Nov 1997)
adrenal weight factor A postulated substance of adenohypophysial origin responsible for maintenance of the weight of the adrenal cortex.
(05 Mar 2000)
adrenocorticotropic releasing factor Hormone produced by hypothalamus that causes pituitary to secrete adrenocorticotropic hormone.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á